Alvin Shih | CEO

Alvin Shih, CEO, Enzyvant

Alvin has served as CEO of Enzyvant since November 2016. Prior to joining Enzyvant, Alvin was the Chief Operating Officer for Rare Diseases at Pfizer, and the global head of R&D at Retrophin. Prior to joining biopharma, he was a healthcare consultant at LEK Consulting and McKinsey & Company. Alvin has an MD from the University of Alabama, an MBA from Northwestern University, and completed his training in internal medicine at the Massachusetts General Hospital.


World Orphan Drug Congress USA 2018 - Conference Day One @ 12:15

Case study: Enzyvant’s approach to developing RVT-802, a novel tissue-based therapeutic for complete DiGeorge Syndrome

  • Leveraging expedited regulatory pathways, including breakthrough designation and Regenerative Medicine Advanced Therapy (RMAT) designation
  • Collaborating with academic partners
  • Fostering advocacy relationships and aligning corporate and patient priorities
  • Developing a commercial model for a transformative, one-time therapy in the pre-launch phase

back to speakers